Factors affecting the uterine sarcomas developement and possibilities of their clinical diagnosis

Česká verzia

Authors: D. Dvorská ^1,2; D. Braný ^1,2; Z. Danková ³; E. Halášová ¹; J. Višňovský ²
Authors place of work: Divízia molekulová medicína, Martinské centrum pre biomedicínu, JLF UK, Martin, riaditeľka divízie prof. RNDr. E. Halášová, PhD. ¹; Gynekologicko-pôrodnícka klinika JLF UK a UNM Martin, prednosta prof. MUDr. P. Žúbor, PhD. ²; Divízia onkológia, Martinské centrum pre biomedicínu, JLF UK, Martin, riaditeľka divízie doc. RNDr. Z. Lasabová, PhD. ³
Published in the journal: Ceska Gynekol 2018; 83(5): 364-370
Category: Original Article

Summary

Objective:

The main goal of this article is to summarize the known factors underlying the tumorigenesis of sarcomas and to present the limitations of clinical diagnosis.

Design:

A review article.

Settings:

Division of Molecular Medicine, Biomedical Center, JLF UK Martin, Slovakia; Department of Gynaecology and Obstetrics JLF UK and UNM Martin, Slovakia; Division of Oncology, Biomedical Center in Martin, JLF UK, Martin, Slovakia.

Methods:

An analysis and summarisation of published studies about etiology, aberrant factors and limmitations of clinical diagnosis of uterne sarcomas.

Results and conclusions:

Uterine sarcomas are heterogenous, malignant tumour types of mesenchymal origin with a very low incidence. On the other hand, sarcomas are very aggressive tumours with a poor prognosis, and a very low chance of surviving in general. The most common types of sarcomas are leiomyosarcomas, followed in percentage occurrence by endometrial stromal sarcomas and adenosarcomas. This tumour pathogenesis remains still relatively unknown. There are recognized only several predisposition factor types, and the limitated molecular-genetic aberrations associated with their occurrence. Importantly, the potential perturbation of the malignant mass during the implementation of invasive methods can be considered as the most serious risk factor. In regards to the visualization methods application, there are still limited ways of distinguishing between malignant and benign forms, especially in the case of leiomyosarcomas.

Keywords:

sarcomas, leiomyosarcomas, mesenchymal tumours, clinical diagnosis

Zdroje

1.   Abeler, VM., Røyne, O., Thoresen, S., et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology, 2009, 54, 3, p. 355–364.
2.   Amant, F., Coosemans, AN., Debiec-Rychter, M., et al. Clinical management of uterine sarcomas. Lancet Oncol, 2009, 10, 12, p. 1188–1198.
3.   Chiang, S., Ali, R., Melnyk, N., et al. Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol, 2011, 35, 9, p. 1364–1372.
4.   Chuang, TD., Ho, M., Khorram, O. The regulatory function of miR-200c on inflammatory and cell-cycle associated genes in SK-LMS-1, a leiomyosarcoma cell line. Reproduct Sci, 2015, 22, 5, p. 563–571.
5.   Cieśla, M., Dulak, J., Józkowicz, A. MicroRNAs and epigenetic mechanisms of rhabdomyosarcoma development. Intern J Biochem Cell Biol, 2014, 53, p. 482–492.
6.   D’Angelo, E., Prat, J. Uterine sarcomas: a review. Gynecol Oncol, 2010, 116, 1, p. 131–139.
7.   Davidson, B., Abeler, VM., Førsund, M., et al. Gene expression signatures of primary and metastatic uterine leiomyosarcoma. Hum Pathol, 2014, 45, 4, p. 691–700.
8.   Davidson, B., Abeler, VM., Hellesylt, E., et al. Gene expression signatures differentiate uterine endometrialstromal sarcoma from leiomyosarcoma. Gynecol Oncol, 2013, 128, 2, p. 349–355.
9.   Diba, C. Incidencia zhubných nádorov v Slovenskej republike 2008. Narodne centrum zdravotnickych informaci, 2014. [http: //www.nczisk.sk/Documents/publikacie/analyticke/incidencia_zhubnych_nadorov_2008.pdf ]
10.   Eastley, CE., Ottolini, B., Neumann, R., et al. Circulating tumour-derived DNA in metastatic soft tissue sarcoma. Oncotaget, 2018, 9, 12, p. 10549–10560.
11.   Falcone, T., Parker, WH. Surgical management of leiomyomas for fertility or uterine preservation. Obstet Gynecol, 2013, 121, 4, p. 856–868.
12.   Giuntoli, RL., Gostout, BS., DiMarco, CS., et al. Diagnostic criteria for uterine smooth muscle tumors, leiomyoma variants associated with malignant behavior. J Reprod Med, 2007, 52, 11, p. 1001.
13.   Guled, M., Pazzaglia, L., Borze, I., et al. Differentiating soft tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma, a miRNA analysis. Genes Chromosomes Cancer, 2014, 53, 8, p. 693–702.
14.   Han, X., Wang, J., Sun, Y. Circulating tumor DNA as a biomarker for cancer detection. Genomic, Proteomics Bioinformatics, 2017, 15, 2, p. 59–72.
15.   Hayashi, T., Horiuchi, A., Sano, K., et al. Mice-lacking LMP2, immuno-proteasome subunit, as and animal model of spontaneous uterine leiomyosarcoma. Protein Cell, 2010, 1, 8, p. 711–717.
16.   Huang, G., Nishimoto, K., Zhou, Z., et al. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res, 2012, 72, 4, p. 908–916.
17.   Hurley, V. Imaging techniques for fibroid detection. Bailliere’s Clin Obstet Gynaecol, 1998, 12, 2, p. 213–224
18.   Jour, G., Scarborough, JD., Jones, RL., et al. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics. Hum Pathol, 2014, 45, 8, p. 1563–1571.
19.   Jung, CK., Jung, JH. Diagnostic use of nuclear beta-catenin expression for the assessment of endometrial stromal tumors. Mod Pathol, 2008, 21, 6, p. 756–763.
20.   Kadlecová, J., Hudeček, R., Mekiňová, L., et al. Histologické typy děložních myomů u pacientek v reprodukčním věku a postmenopauze. Čes Gynek, 2015, 80, 5, s. 360–364.
21.   Keller, AM., El-Mallah, MK., Flotte, TR. Gene Therapy 2017: Progress and future directions. Clin Transl Sci, 2017, 10, p. 242–248.
22.   Khera, N., Rajput, S. Therapeutic potential of small molecule inhibitors. J Cellular Biochemistry, 2017, 118, 5, p. 959–961.
23.   Kitajima, K., Murakami, K., Kaji, Y., et. al. Spectrum of FDG PET/CT findings of uterine tumors. Amer J Roentgenol, 2010, 195, 3, p. 737–743.
24.   Kleinerman, RA., Yu, CL., Little, MP., et al. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol, 2012, 30, 9, p. 950–957.
25.   Kobayashi, H., Uekuri, C., Akasaka, J., et al. The biology of uterine sarcomas: A review and update. Molecul Clinic Oncol, 2013, 1, 4, p. 599–609.
26.   Koivisto-Korander, R. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumor Biol, 2011, 32, 3, p. 451–459.
27.   Levine, D. Pelvic Doppler. Seminars in Ultrasound, CT and MRI. 1999, 20, 4, p. 239–249.
28.   Mehine, M., Kaasinen, E., Mäkinen, N., et al. Characterization of uterine leiomyomas by whole genome sequencing. N Engl J Med, 2013, 369, 1, p. 43–53.
29.   Mendell, JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell, 2008, 133, 2, p. 217–222.
30.   Műller, R., Břeský, P. Obrovský děložní myom – kazuistika. Čes Gynek, 2016, 81, 1, s. 71–75.
31.   Rha, SE., Byun, JY., Jung, SE., et al. CT and MRI of uterine sarcomas and their mimickers. Amer J Roentgenol, 2003, 181, 5, p. 1369–1374.
32.   Samuel, A., Fennesy, FM., Tempany, CM., et al. Avoiding treatment of leiomyosarcomas: the role of magnetic resonance in focused ultrasound surgery. Fertil Steril, 2008, 90, 3, p. 850.e9
33.   Schmidt, LS., Linehan, WM. Hereditary leiomyomatosis and renal cell carcinoma. Intern J Nephrol Renovascular Dis, 2014, 7, p. 253.
34.   Schwartz, LB., Zawin, M., Carcangiu, ML., et al. Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata? Fertil Steril, 1998, 70, 3, p. 580.
35.   Seidel, C., Bartel, F., Rastetter, M., et al. Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer, 2005, 114, 3, p. 442–447.
36.   Shozu, M., Murakami, K., Inoue, M., et al. Aromatase and leiomyoma of uterus. Seminars in reproductive medicine, 2004, 22, 1, p. 51–60.
37.   Skubitz, KM., Skubitz, PN. Differential gene expression in leiomyosarcoma. Cancer, 2003, 98, 5, p. 1029–1038.
38.   Špaček, J., Laco, J., Petera, J., et al. Prognostické faktory u mezenchymálních a smíšených nádorů děložního těla. Čes Gynek, 2009, 74, 4, s. 292–297.
39.   Tal, R., Segars, JH. The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. Hum Reprod Update, 2014, 20, 2, p. 194–216.
40.   Tanaka, YO., Nishida, M., Tsunoda, H., et al. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings. J Magn Reson Imaging, 2004, 20, 6, p. 998.
41.   Tanic, M., Beck, S. Cell-free DNA: Treasure trove for cancer medicine. Nature Materials, 2017, 16, 11, p. 1056.
42.   Taulli, R., Bersani, F., Foglizzo, V., et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest, 2009, 119, 8, p. 2366–2378.
43.   Tomšová, M., Pohnětalová, D., Špaček, J. Vzácné nádory myometria – intravenózní leiomyomatóza a benigní metastázujíci leiomyom. Čes Gynek, 2007, 72, 2, p. 136–139.
44.   Tropé, CG., Abeler, VM., Kristensen, GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncologica, 2012, 51, 6, p. 694–705.
45.   Ünver, NU., Acikalin, MF., Öner, Ü., et al. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors. Arch Gynecol Obstet, 2011, 284, 2, p. 483–490.
46.   Van den Bosch, T., Coosemans, A., Morina, M., et al. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol, 2012, 26, 2, p. 257–266.
47.   Wickerham, DL., Fisher, B., Wolmark, N., et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol, 2002, 20, 11, p. 2758–2760.
48.   Winbanks, CE., Beyer, C., Hagg, A., et al. miR-206 represses hypertrophy of myogenic cells but not muscle fibers via inhibition of HDAC4. PLoS One, 2013, 8, 9, p. e73589.
49.   Wu, Y., Li, C., Zhong, Y., et al. Head and neck rhabdomyosarcoma in adults. J Craniofac Surg, 2014, 25, 3, p. 922–925.
50.   Xing, D., Scangas, G., Nitta, M., et al. A role for BRCA1 in uterine leiomyosarcoma. Cancer Res, 2009, 69, 21, p. 8231–8235.
51.   Yan, D., Dong, XE., Chen, X., et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem, 2009, 284, 43, p. 29596–29604.
52.   Yin, L., Cai, WJ., Liu, CX., et al. Analysis of PTEN methylation patterns in soft tissue sarcomas by MassARRAY spectrometry. PLoS One, 2013, 8, 5, p. e62971.